DOCSLIB.ORG

Prescribing Guidelines for Domperidone

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prescribing Guidelines for Domperidone Prescribing Guidelines for Domperidone (Includes risk of cardiac side effects – restricted indication, new contraindications, reduced dose & duration of use). A European review assessed the benefits and risks of domperidone following continued reports of cardiac side effects. The review confirmed a small increased risk of serious cardiac side effects. A higher risk was observed in: Those over the age of 60 years People taking daily oral domperidone doses of more than 30mg Those taking QT-prolonging medicines or CYP3A4 inhibitors at the same time as domperidone. For indications other than nausea and vomiting, the benefits were not considered to outweigh the cardiac risk. Based on these results of this review, the MHRA issued revised advice in April 2014 on the use of domperidone. Domperidone is restricted to the relief of symptoms of nausea and vomiting and the dosage and duration of use have also been reduced. Domperidone is now contraindicated in those: with conditions where cardiac conduction is, or could be, impaired. with underlying cardiac diseases such as congestive heart failure. receiving other medications known to prolong QT or potent CYP3A4 inhibitors. with severe hepatic impairment. Patients with these conditions should have their treatment reviewed at their next routine appointment and be switched to an alternative treatment if required. Oral liquid formulations of domperidone should only be given via an appropriately designed, graduated oral syringe to ensure dose accuracy. Recommended dose: Adults and adolescents over 12 years of age and weighing ≥35kg, the recommended maximum dose in 24 hours is 30mg (dose interval: 10mg up to three times daily). (Maximum treatment duration should not exceed one week) Domperidone is no longer licensed for use in children younger than 12 years or those weighing less than 35 kg (MHRA December 2019). Patients currently receiving long-term treatment with domperidone should be reassessed at a routine appointment to advise on treatment continuation, dose change, or cessation. Advice to give to patients Domperidone should only be used for short periods of time to treat nausea and vomiting. Talk to a doctor straight away if you experience dizziness; fainting; chest pain; or a rapid, fluttering, or pounding heartbeat while taking domperidone. Availability of domperidone Domperidone is no longer available without prescription. People now need to have a medical assessment before taking domperidone to determine if it is suitable for them due to the risk of cardiac side effects. Produced by West Essex CCG Medicines Optimisation Team August 2014; Updated and Approved MOPB September 2019; Updated and Approved MOPB January 2020 following MHRA Safety update. Clinical use of domperidone across indications following the MHRA advice UKMI Summary: current position and available advice on the use of domperidone (May 2014) Domperidone is used for a number of unlicensed and other indications not covered directly by the MHRA’s advice. Patients for whom domperidone might be considered currently include: 1. Adults with gastro-oesophageal reflux disease, dyspepsia, or gastroparesis 2. Adults receiving chemotherapy, for the prevention of nausea and vomiting 3. Children with gastro-oesophageal reflux disease 4. Breast feeding women where domperidone is used to stimulate milk production (i.e. as a galactogogue) A number of publications have now been produced to help guide recommendations and prescribing in these areas. 1. Adults with gastro-oesophageal reflux disease, dyspepsia, or gastroparesis A UKMi rapid communication produced in May 2014 summarised potential options for these indications. It suggests: Reviews for all patients receiving long-term domperidone should be undertaken with a view to undertaking a trial withdrawal in conjunction with optimising other treatment options for GORD and dyspepsia. For patients with gastroporesis, ‘on-demand’ domperidone (i.e. up to 10mg three times daily for up to 1 week) continues to be an option mindful of the revised contraindications. 2. Adults receiving chemotherapy, for the prevention of nausea and vomiting As prescribing here involves higher (unlicensed) doses of domperidone, our advice would be that this is outside the expertise of a GP; therefore the prescribing and clinical responsibility, in this case should remain with the specialist. 3. Children with gastro-oesophageal reflux disease The Neonatal and Paediatric Pharmacists’ Group produced advice on the use of domperidone in infants and children (May 2015). It discusses a variety of courses of action dependent on whether treatment is established or being considered, and whether congenital heart disease is present. Consider reviewing children with established GORD who are already taking domperidone. In general, as stated by the MHRA advice, domperidone should only be used for the relief of the symptoms of nausea and vomiting In patients who are newly diagnosed with GORD, follow the NICE NG1 guidance (January 2015) for the initial and pharmacological management of GORD. Domperidone should only be prescribed for children by a specialist, and only if the benefits of using domperidone to treat GORD outweigh the risks of the cardiac adverse events (MOPB September 2019). Medicines for Children have a leaflet for parents and carers entitled Domperidone for gastro-oesophageal reflux. 4. Use in nursing mothers to promote lactation (i.e. use as a galactogogue) UKMI: Drug treatment of inadequate lactation (October 2014) A health professional should always be involved in the decision to use a galactagogue. Drugs to manage inadequate lactation should only be used where there is objective evidence to support diagnosis and where non- drug methods have failed. There are no drugs licensed in the UK to improve lactation. As long as the possible cardiac effects are taken into account, domperidone is considered to be the agent of choice for inadequate lactation because of its superior side effect profile, efficacy, and minimal passage into breast milk. Domperidone should not be used for inadequate lactation where the mother or infant has a cardiac disorder or are receiving treatment with drugs known to affect the QT interval e.g. ketoconazole or erythromycin, in which case metoclopramide is preferred. A maternal daily dose of 30mg domperidone should not be exceeded. The maximum treatment duration should not usually exceed one week. References 1. European Medicines Agency Statement Domperidone-containing medicines (April 2014) 2. MHRA Domperidone: risks of cardiac side effects (May 2014) 3. MHRA Domperidone: small risk of heart problems (May 2014) Information for patients 4. MHRA Domperidone: no longer available without prescription (September 2014) 5. UKMI Summary: current position and available advice on the use of domperidone (May 2014) 6. UKMI Domperidone: new restrictions in use (May 2014) 7. UKMI Medicines Q&As Drug treatment of inadequate lactation (October 2014) 8. MHRA Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents (December 2019) Produced by West Essex CCG Medicines Optimisation Team August 2014; Updated and Approved MOPB September 2019; Updated and Approved MOPB January 2020 following MHRA Safety update. .
Load more

Recommended publications
  • What Are the Acute Treatments for Migraine and How Are They Used?
    2. Acute Treatment CQ II-2-1 What are the acute treatments for migraine and how are they used? Recommendation The mainstay of acute treatment for migraine is pharmacotherapy. The drugs used include (1) acetaminophen, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans and (5) antiemetics. Stratified treatment according to the severity of migraine is recommended: use NSAIDs such as aspirin and naproxen for mild to moderate headache, and use triptans for moderate to severe headache, or even mild to moderate headache when NSAIDs were ineffective in the past. It is necessary to give guidance and cautions to patients having acute attacks, and explain the methods of using medications (timing, dose, frequency of use) and medication use during pregnancy and breast-feeding. Grade A Background and Objective The objective of acute treatment is to resolve the migraine attack completely and rapidly and restore the patient’s normal functions. An ideal treatment should have the following characteristics: (1) resolves pain and associated symptoms rapidly; (2) is consistently effective; (3) no recurrence; (4) no need for additional use of medication; (5) no adverse effects; (6) can be administered by the patients themselves; and (7) low cost. Literature was searched to identify acute treatments that satisfy the above conditions. Comments and Evidence The acute treatment drugs for migraine generally include (1) acetaminophens, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans, and (5) antiemetics. For severe migraines including status migrainosus and migraine attacks refractory to treatment, (6) anesthetics, and (7) corticosteroids (dexamethasone) are used (Tables 1 and 2).1)-9) There are two approaches to the selection and sequencing of these medications: “step care” and “stratified care”.
    [Show full text]
  • Drugs That Can Cause Delirium (Anticholinergic / Toxic Metabolites)
    Drugs that can Cause Delirium (anticholinergic / toxic metabolites) Deliriants (drugs causing delirium) Prescription drugs . Central acting agents – Sedative hypnotics (e.g., benzodiazepines) – Anticonvulsants (e.g., barbiturates) – Antiparkinsonian agents (e.g., benztropine, trihexyphenidyl) . Analgesics – Narcotics (NB. meperidine*) – Non-steroidal anti-inflammatory drugs* . Antihistamines (first generation, e.g., hydroxyzine) . Gastrointestinal agents – Antispasmodics – H2-blockers* . Antinauseants – Scopolamine – Dimenhydrinate . Antibiotics – Fluoroquinolones* . Psychotropic medications – Tricyclic antidepressants – Lithium* . Cardiac medications – Antiarrhythmics – Digitalis* – Antihypertensives (b-blockers, methyldopa) . Miscellaneous – Skeletal muscle relaxants – Steroids Over the counter medications and complementary/alternative medications . Antihistamines (NB. first generation) – diphenhydramine, chlorpheniramine). Antinauseants – dimenhydrinate, scopolamine . Liquid medications containing alcohol . Mandrake . Henbane . Jimson weed . Atropa belladonna extract * Requires adjustment in renal impairment. From: K Alagiakrishnan, C A Wiens. (2004). An approach to drug induced delirium in the elderly. Postgrad Med J, 80, 388–393. Delirium in the Older Person: A Medical Emergency. Island Health www.viha.ca/mhas/resources/delirium/ Drugs that can cause delirium. Reviewed: 8-2014 Some commonly used medications with moderate to high anticholinergic properties and alternative suggestions Type of medication Alternatives with less deliriogenic
    [Show full text]
  • Cabergoline Patient Handout
    Cabergoline For the Patient: Cabergoline Other names: DOSTINEX® • Cabergoline (ca-BERG-go-leen) is used to treat cancers that cause the body to produce too much of a hormone called prolactin. Cabergoline helps decrease the size of the cancer and the production of prolactin. It is a tablet that you take by mouth. • Tell your doctor if you have ever had an unusual or allergic reaction to bromocriptine or other ergot derivatives, such as pergoline (PERMAX®) and methysergide (SANSERT®), before taking cabergoline. • Blood tests and blood pressure measurement may be taken while you are taking cabergoline. The dose of cabergoline may be changed based on the test results and/or other side effects. • It is important to take cabergoline exactly as directed by your doctor. Make sure you understand the directions. Take cabergoline with food. • If you miss a dose of cabergoline, take it as soon as you can if it is within 2 days of the missed dose. If it is over 2 days since your missed dose, skip the missed dose and go back to your usual dosing times. • Other drugs such as azithromycin (ZITHROMAX®), clarithromycin (BIAXIN®), erythromycin, domperidone, metoclopramide, and some drugs used to treat mental or mood problems may interact with cabergoline. Tell your doctor if you are taking these or any other drugs as you may need extra blood tests or your dose may need to be changed. Check with your doctor or pharmacist before you start or stop taking any other drugs. • The drinking of alcohol (in small amounts) does not appear to affect the safety or usefulness of cabergoline.
    [Show full text]
  • PRESCRIBED DRUGS and NEUROLOGICAL COMPLICATIONS K a Grosset, D G Grosset Iii2
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2004.045757 on 16 August 2004. Downloaded from PRESCRIBED DRUGS AND NEUROLOGICAL COMPLICATIONS K A Grosset, D G Grosset iii2 J Neurol Neurosurg Psychiatry 2004;75(Suppl III):iii2–iii8. doi: 10.1136/jnnp.2004.045757 treatment history is a fundamental part of the healthcare consultation. Current drugs (prescribed, over the counter, herbal remedies, drugs of misuse) and how they are taken A(frequency, timing, missed and extra doses), drugs tried previously and reason for discontinuation, treatment response, adverse effects, allergies, and intolerances should be taken into account. Recent immunisations may also be of importance. This article examines the particular relevance of medication in patients presenting with neurological symptoms. Drugs and their interactions may contribute in part or fully to the neurological syndrome, and treatment response may assist diagnostically or in future management plans. Knowledge of medicine taking behaviour may clarify clinical presentations such as analgesic overuse causing chronic daily headache, or severe dyskinesia resulting from obsessive use of dopamine replacement treatment. In most cases, iatrogenic symptoms are best managed by withdrawal of the offending drug. Indirect mechanisms whereby drugs could cause neurological problems are beyond the scope of the current article—for example, drugs which raise blood pressure or which worsen glycaemic control and consequently increase the risk of cerebrovascular disease, or immunosupressants
    [Show full text]
  • NEUROPHARMACOLOGICAL COMPARISON BETWEEN DOMPERIDONE and METOCLOPRAMIDE Abstract-Domperidone, a New Gastrokinetic with Potent
    In in vitro binding assays, domperidone In in vitro experiments on the isolated was found to be a potent and specific guinea-pig stomach, domperidone selectively dopamine antagonist, but ex vivo and in vivo NEUROPHARMACOLOGICAL COMPARISON BETWEEN DOMPERIDONE AND METOCLOPRAMIDE A. WAUQUIER, C.J.E. NIEMEGEERS and P.A.J. JANSSEN Department of Pharmacology, Janssen Pharmaceutica , B-2340 Beerse, Belgium Accepted October 17, 1980 Abstract-Domperidone, a new gastrokinetic with potent antiemetic properties is devoid of central effects, up to high dose levels. To assess the CNS activity of domperidone and metoclopramide, the inhibition of intracranial self-stimulation (ICS) in two different situations, and the influence on EEG in dogs were studied. The dissociation between the antiemetic and central effects of both compounds were evaluated in dogs given a stereotypogenic dose of apomorphine. A significant and dose related inhibition of ICS (conditioned situation) was obtained with 0.8 and 1.6 mg/kg i.v. domperidone and with 0.125, 0.25 and 0.50 mg/kg i.v. metoclopramide. The ED50 values were 0.79 mg/kg and 0.25 mg/kg respectively. The effect was most pronounced 4 hr after administration with domperidone and 15 min after administration with metoclopramide. In the EEG studies, no specific structure-related effects were found but the total potency was increased with domperidone 0.8 and 1.6 mg/kg i.v. and with metoclopramide 0.063, 0.125, 0.25 and 0.50 mg/kg i.v. This increase was due to a decrease in fast frequencies, an increase of slower frequencies and a slight increase of the amplitude.
    [Show full text]
  • Domperidone Packet
    Domperidone IND Packet For Sponsors Treating Patients with Gastrointestinal Disorders Last Updated February 2, 2021 Page 1 1. Domperidone Background ...................................................................................................................................................... 3 2. Obtaining an IND..................................................................................................................................................................... 3 3. Application Process ................................................................................................................................................................. 3 Single Patient IND (SPI) .............................................................................................................................................................. 4 Intermediate Size Patient Population (multi-patient) IND ........................................................................................................... 4 4. Regulatory Responsibilities as a Sponsor ............................................................................................................................... 5 5. Ordering Domperidone........................................................................................................................................................... 5 6. Financial Responsibility .........................................................................................................................................................
    [Show full text]
  • Endoscopic Treatment of Pharmacobezoar Caused by Slow-Release Clomipramine and Quetiapine Overdose
    Netherlands Journal of Critical Care Submitted August 2020; Accepted January 2021 CASE REPORT Endoscopic treatment of pharmacobezoar caused by slow-release clomipramine and quetiapine overdose S.J.P. Hiel1, A. Osinski1, J.T. Kamphuis2 1Department of Intensive Care, 2Department of Gastroenterology, Maxima Medical Center, Veldhoven, the Netherlands Correspondence S.J.P. Hiel - [email protected] Keywords - slow-release clomipramine, intoxication, pharmacobezoar, endoscopy Abstract Case report A pharmacobezoar is a rare entity characterised by an An 18-year-old female known with chronic depression was accumulation of undigested pills in the gastrointestinal tract. admitted to our hospital approximately two hours after taking It is often induced by massive drug consumption, especially an overdose of tablets. She supposedly ingested 50 tablets of slow-release tablets. We describe an 18-year-old female with slow-release clomipramine 75 mg (3.75 g total) and 100 tablets a pharmacobezoar after taking an overdose of slow-release of slow-release quetiapine 25 mg (2.5 g total). She was found clomipramine and slow-release quetiapine. Because of a in a state of reduced responsiveness by her mother who called decline in her level of consciousness, she was intubated. As the emergency services. standard treatment with activated charcoal, gastric lavage On examination at the emergency department, a very thin and laxatives was insufficiently effective, it was decided patient with a body weight of 50 kg (body mass index of 17.3 to remove the tablets endoscopically. The patient did not kg/m2) was seen. Glasgow coma scale (GCS) was E3-M5-V3. have any post-procedural complications and showed a full Her pupils were slightly, equally dilated and responsive to recovery.
    [Show full text]
  • Therapy and Symptom Management in CFS/ME
    British Association for CFS/ME: Therapy and Symptom Management in CFS/ME Aim This guide was developed through the British Association of CFS/ME (BACME), an organisation that represents health professionals working with this condition. It aims to provide information to support clinicians in their work with CFS/ME and includes both pharmacological and rehabilitative approaches. It has been developed by a group of experienced professionals both in a specially convened open workshop, held in 2014, and through circulation and consultation with the wider BACME membership, AYME (Action for Young people with ME) and service -users. This document is compiled of two major sections. These two sections are: 1. Symptom management guide. This provides information about symptoms experienced by people with CFS/ME, and if pharmacological therapy can ease these symptoms. Information on contra-indications and cautions to consider is also provided for these pharmacological treatments. 2. Guidance for therapists covering the provision of therapy for CFS/ME. This includes a list of resources (available on the website BACME.org.uk) for use in therapy, as well as guidance on support and supervision. It does not replace specialist CBT and GET training (recommended by NICE and available at www.PACEtrial.org). It represents pragmatic recommendations from experienced clinicians to guide practice when seeing adults with CFS/ME, where specialist CFS/ME CBT and GET therapists are not available/appropriate. It is informed by these approaches. The term CFS/ME has been applied throughout this guide as it is the current term used in NHS services. Other terminology may be used by some clinicians, therapists and service users A Brief History of CFS/ME services within NHS In May 2003, it was announced that a central budget of £8.5 million would be released to the NHS in two phases to allow stepped development of CFS/ ME services in England.
    [Show full text]
  • Prescriber Update Vol.36 No.1 March 2015
    Prescriber Update Vol. 36 No. 1 March 2015 www.medsafe.govt.nz ISSN 1172-5648 (print) ISSN 1179-075X (online) Contents A Topical Issue – Serious Hypersensitivity and Burning Reactions 2 Atomoxetine and Raynaud’s Phenomenon 3 Check INR after Starting Roxithromycin for Patients on Warfarin 3 Fruit Interactions with Common Medicines 4 Sexual Dysfunction Associated with Antidepressants and Antipsychotics 5 Rotavirus Vaccination – Summary of Adverse Event Reports Received in the First Six Months of Funding 8 MARC’s Remarks: December 2014 Meeting 8 Risk of Stroke with Ranibizumab (Lucentis), Bevacizumab (Avastin) and Aflibercept (Eylea), Administered by Intravitreal Injection 9 Medicine Labels – Rubbing Salt into the Wound 10 Domperidone – At the Heart of the Matter 10 Adverse Reaction Reporting in New Zealand – 2014 12 Spontaneous Reports: Seasonal Influenza Vaccination 2014 13 MEDICINES MONITORING 13 Preventing Paediatric Medication Errors 14 A Topical Issue — Serious Hypersensitivity and Burning Reactions There have been reports internationally Key Messages of chemical skin burns in premature neonates who were treated with chlorhexidine solution z Serious hypersensitivity reactions before central venous catheterisation3. This risk including anaphylaxis have been reported has been associated with both alcohol-based and following the use of topical acne products water-based solutions. that contain benzoyl peroxide or salicylic acid. According to these reports and the published literature, the risk appears to be higher z There is a risk of chemical skin burns with in premature neonates, especially those born the use of chlorhexidine solution for skin before 32 weeks of gestation and within the first disinfection in premature neonates. two weeks of life.
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]
  • Proposal for the Inclusion of Anti-Emetic Medications (For Children) in the Who Model List of Essential Medicines
    Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines Geneva, 29 September to 3 October 2008 PROPOSAL FOR THE INCLUSION OF ANTI-EMETIC MEDICATIONS (FOR CHILDREN) IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES REPORT Marc Bevan, Elizabeth Seil, Robin Bell and Jane Robertson Discipline of Clinical Pharmacology School of Medicine and Public Health Faculty of Health University of Newcastle Level 5, Clinical Sciences Building, NM2 Calvary Mater Hospital Edith Street, Waratah, 2298 New South Wales AUSTRALIA Tel +61-02-49211726 Fax + 61-02-49602088 WHO EML – anti-emetics – June 2008 1. Summary statement of the proposal Anti-emetic medications (anti-histamines, dopamine antagonists and serotonin 5-HT3 antagonists) are proposed for inclusion in the World Health Organization (WHO) Model List of Essential Medicines for the management of acute gastroenteritis in children. 2. Name of focal point in WHO submitting or supporting the application 3. Name of the organisation preparing the application Discipline of Clinical Pharmacology, School of Medicine and Public Health, Faculty of Health, University of Newcastle, Level 5, Clinical Sciences Building, NM2, Calvary Mater Hospital, Edith Street, Waratah, 2298, New South Wales, Australia. 4. International Nonpropriety Name (INN, generic name) of the medicine The proposal reviews relevant data regarding four anti-emetic medications; metoclopramide and domperidone (dopamine agonists), promethazine (anti- histamine) and ondansetron (serotonin 5-HT3 antagonist). 5. Formulation considered for inclusion The formulations of metoclopramide, domperidone, promethazine and ondansetron considered for inclusion are shown in Table 1. Table 1: Formulations of ant-emetic medications considered for inclusion Formulation Comment Metoclopramide Injection or oral - Injection, tablet and oral liquid formulations are preparation (tablet, currently listed on WHO EML for children.
    [Show full text]
  • RP-HPLC Method for Determination of Several Nsaids and Their Combination Drugs
    Hindawi Publishing Corporation Chromatography Research International Volume 2013, Article ID 242868, 13 pages http://dx.doi.org/10.1155/2013/242868 Research Article RP-HPLC Method for Determination of Several NSAIDs and Their Combination Drugs Prinesh N. Patel, Gananadhamu Samanthula, Vishalkumar Shrigod, Sudipkumar C. Modh, and Jainishkumar R. Chaudhari Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Andhra Pradesh 500037, India Correspondence should be addressed to Gananadhamu Samanthula; [email protected] Received 29 June 2013; Accepted 13 October 2013 Academic Editor: Andrew Shalliker Copyright © 2013 Prinesh N. Patel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. An RP-HPLC method for simultaneous determination of 9 NSAIDs (paracetamol, salicylic acid, ibuprofen, naproxen, aceclofenac, diclofenac, ketorolac, etoricoxib, and aspirin) and their commonly prescribed combination drugs (thiocolchicoside, moxifloxacin, clopidogrel, chlorpheniramine maleate, dextromethorphan, and domperidone) was established. The separation was performed on ∘ Kromasil C18 (250 × 4.6 mm, 5 m) at 35 C using 15 mM phosphate buffer pH 3.25 and acetonitrile with gradient elution ata flow rate of 1.1 mL/min. The detection was performed by a diode array detector (DAD) at 230 nm with total run time of 30min. 2 Calibration curves were linear with correlation coefficients of determinationr ( ) > 0.999. Limit of detection (LOD) and Limit of quantification (LOQ) ranged from 0.04 to 0.97 g/mL and from 0.64 to 3.24 g/mL, respectively.
    [Show full text]